How the ladders work
Every GLP-1 label follows the same logic: start low for the gut, climb slow for tolerability, stop climbing when the dose does its job. The starting doses are deliberately sub-therapeutic; the Ozempic label says plainly that 0.25 mg is not effective for glycemic control. Each step up waits at least 4 weeks, because the gut side effects cluster around escalations, and the nausea, diarrhea and sulfur burp weeks are usually escalation weeks.
The distinction that matters: titration vs maintenance
Not every rung is a destination. The clearest case is Zepbound: the label names 5, 10 and 15 mg as maintenance doses, and Lilly describes 7.5 and 12.5 mg as titration steps between them. Meanwhile Ozempic's ladder treats everything from 0.5 mg upward as a usable dose, and Wegovy names 1.7 mg as a fallback maintenance dose for people who cannot hold 2.4 mg. Knowing which kind of rung you are standing on changes the conversation with your prescriber: "can I stay here" has a different answer on a maintenance rung than on a titration step. The deeper version of that conversation, including staying below the labeled doses, lives in the microdosing chart.
The top rung is not the goal
The ladders read like progressions, so people treat the top like the finish line. The labels say otherwise: the goal is the lowest dose that holds the effect. Plateauing at a middle dose is not underachieving, and escalating past a dose that was working costs side effects without buying much. If a stall is what is pushing you up the ladder, read the plateau guide first: a stall at a steady weight is usually energy balance doing exactly what it does, not the medication failing. And the question of which dose you stay on long-term is the maintenance dose guide's whole subject.
Coming down the ladder
The labels only describe the climb. There is no FDA-approved descent, which is its own remarkable fact given how many people eventually stop. What exists instead: published de-escalation patterns, the pharmacology of the washout curve, and prescriber judgment. The taper schedule visualizer shows what stepping down does to your drug level, and the weaning guide covers the conversation itself. If your dosing has gone irregular for supply or cost reasons rather than by choice, the missed dose guide and the affordability guide are the practical pages.
Frequently asked questions
What is the maximum dose of Ozempic?
2 mg once weekly is the top of the Ozempic label. Wegovy, the same molecule labeled for weight management, climbs further to 2.4 mg. That difference is the labels, not the chemistry: semaglutide is semaglutide, but each label was approved with its own ladder and its own studied endpoint.
Why do all these medications start at a dose that barely does anything?
Tolerability. The starting doses (0.25 mg semaglutide, 2.5 mg tirzepatide) exist to let the gut adapt before the therapeutic doses arrive; the Ozempic label states outright that 0.25 mg is not effective for glycemic control. The first month is an on-ramp, and feeling underwhelmed during it is the schedule working as designed.
How long do you stay at each dose before increasing?
At least 4 weeks per step on every one of the four labels. Prescribers can hold a rung longer, and the Wegovy label explicitly allows delaying escalation when a step is rough. Faster than 4 weeks is off-label territory.
Is 7.5 mg of Zepbound a maintenance dose?
Not per Lilly. The label names 5, 10 and 15 mg as the maintenance doses, and Lilly Medical describes 7.5 and 12.5 mg as titration steps between them. In practice plenty of people stay at 7.5 mg with their prescriber’s blessing and do fine; that is a clinical judgment call layered on top of the label, and it is worth knowing which kind of dose you are on.
Do you have to reach the highest dose?
No. The ladders are ceilings, not destinations. The label-sanctioned goal is the lowest dose that achieves the effect: Ozempic names 0.5 mg as a legitimate place to stay, Wegovy names 1.7 mg as a maintenance option, and Zepbound names 5 mg as a full maintenance dose. Escalation is for when the current rung stops being enough, which is a conversation, not an automatic climb.
Are Ozempic and Wegovy doses interchangeable?
They are the same molecule on different labels with different ladders, and pens deliver different strengths. Insurance treats them as different products too. If you are switching between them, or from either to tirzepatide, the dose mapping question belongs to your prescriber; there is no official equivalence table.
Sources
- Ozempic prescribing information: Ozempic (semaglutide) full prescribing information, via DailyMed (NIH).
- Wegovy prescribing information: Wegovy (semaglutide) full prescribing information, via DailyMed (NIH).
- Zepbound prescribing information: Zepbound (tirzepatide) full prescribing information, via DailyMed (NIH).
- Mounjaro prescribing information: Mounjaro (tirzepatide) full prescribing information, via DailyMed (NIH).
- Lilly on Zepbound maintenance doses: Eli Lilly Medical: why Zepbound 7.5 mg and 12.5 mg are titration steps rather than maintenance doses; 5, 10 and 15 mg are the label maintenance doses.
- All ladder structure, escalation intervals and dose roles restate the current FDA prescribing information for each product; labels are revised, so confirm against the current label with your prescriber or pharmacist.
Linked citations open on PubMed or DailyMed, both run by the US National Institutes of Health. Where a claim on this page comes from reporting or clinical commentary we could not resolve to a stable public record, it is listed above without a link rather than pointed at an approximation.